Company intelligence / Profile preview

MaxWell Biosystems

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

MaxWell Biosystems develops and markets advanced high-content electrophysiology platforms that enable detailed recording and analysis of electrical activity from neurons and other electrogenic cells. Their systems are widely used in preclinical drug discovery, safety pharmacology, disease modeling, phenotypic screening, toxicity testing, and basic neuroscience research. The company’s products are commercialized globally to academic labs and pharmaceutical industry partners. No clinical results as the company does not develop therapeutics.

Modalities: Device (High-density microelectrode array)Software platform for electrophysiology
Industry: Drug Discovery Services

Partnerships

Close collaboration with Bio Engineering Laboratory at ETH ZurichSupported by Venture Kick business competition and >>venture>> program

Beyond the preview

Go deeper on MaxWell Biosystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MaxWell Biosystems.

Explore the full profile